Study of the reliability of serum vascular endothelial growth factor and its soluble receptor as markers of diabetic nephropathy in type 2 diabetes patients

Sumaya B. Abdulrahman; Eman S. Saleh; Sabah M. Saeedi

doi:10.53730/ijhs.v6nS6.10635

Authors

Sumaya B. Abdulrahman
somaia.baher1200m@copharm.uobaghdad.edu.iq
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq
Eman S. Saleh Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad, Baghdad, Iraq
Sabah M. Saeedi Ministry of Health and Environment, Wasit Health Directorate, Wasit, Iraq

Keywords:

T2DM, Diabetic nephropathy, VEGF-A, sVEGFR-1, ACE inhibitors

Abstract

The levels of circulating angiogenic and anti-angiogenic factors, namely vascular endothelial growth factor–A (VEGF-A) and soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), have been linked to the development of renal dysfunction due to the proliferation of microvasculature within the kidneys of type 2 diabetic (T2DM) patients. The study aims to scrutinize serum levels of VEGF and sVEGFR-1 in a sample of Iraqi diabetic nephropathy patients to support their reliability as markers for the prediction of nephropathy in type 2 diabetes mellitus patients as well as to assess the ACE inhibitor’s effect on the levels of these two markers. Method: The ninety participants of this case-control study were split into three groups: thirty-five patients with T2DM and an equal number of patients with DN and the third group involve twenty apparently healthy individuals as the control group. The two diabetic groups have been further divided into four groups according to the ACE inhibitors use. Laboratory measurements involve the glycemic indices, renal function test with serum VEGF-A and sVEGFR-1. Results: the median serum levels of VEGF-A show valuable discrepancies between the three groups (p-value<0.05) but for sVEGFR-1 it doesn’t show a notable difference between the DM and the DN groups only(p-value> 0.05).

Downloads

Download data is not yet available.

References

Aly MH, Arafat MA, Hussein OA, Elsaid HH, Abdel-Hammed AR. Study of Angiopoietin-2 and vascular endothelial growth factor as markers of diabetic nephropathy onset in Egyptians diabetic patients with non-albuminuric state. Diabetes Metab Syndr Clin Res Rev [Internet]. 2019;13(2):1623–7. Available from: https://doi.org/10.1016/j.dsx.2019.03.016

Bus P, Scharpfenecker M, Wilk P Van Der, Wolterbeek R, Bruijn JA, Baelde HJ. The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes. 2017;

Cai M, Wang K, Murdoch CE, Gu Y, Ahmed A. Heterodimerisation between VEGFR-1 and VEGFR-2 and not the homodimers of VEGFR-1 inhibit VEGFR-2 activity. Vascul Pharmacol. 2017;88:11-20. doi: 10.1016/j.vph.2016.11.007.

Care D, Suppl SS. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(January):S15–33.

Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci, 2006, 63(5):601–615.

Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP. Circulating plasma vascular endothelial growth factor and microvascular complications of type I diabetes mellitus: The influence of ACE inhibition. Diabet Med. 2001;18(4):288–94.

Damayanti, I. A. M., Indrayoni, P., Antari, N. W. S., & Padmiswari, A. A. I. M. (2021). Effectiveness of Averrhoa bilimbi leaf extract on spermatogenic cells of mice (Mus Musculus L.) hyperglycemia. International Journal of Health & Medical Sciences, 4(2), 273-279. https://doi.org/10.21744/ijhms.v4n2.1747

Failla CM, Carbo M, Morea V. Positive and negative regulation of angiogenesis by soluble vascular endothelial growth factor receptor-1. Int J Mol Sci. 2018;19(5).

Futrakul N, Futrakul P. Biomarker for early renal microvascular and diabetic kidney diseases. Ren Fail 2017;39(1):505e11.

Hanefeld M, Appelt D, Engelmann K, Sandner D, Bornstein SR, Ganz X, et al. Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy. Horm Metab Res. 2016;48(8):529–34.

Hussin HY, Hussein WA, Ibrahim SAE, Almhdi SA, Abdrabo AA. Association of serum vascular endothelial growth factor levels with nephropathy and retinopathy in type 2 diabetic patients. Pakistan J Med Heal Sci. 2021;15(1):252–5.

Jabbar TL, Kasim AA. Association of retinol binding protein- 4 (RBP4) with glycemia, dyslipidemia, hypertension, and obesity in type 2 diabetic Iraqi patients. Iraqi J Pharm Sci. 2021;29(2):263–70.

Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 2005;67(1):167–77.

Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437(2):169-83. doi: 10.1042/BJ20110301.

Kolatsi-joannou M. Molecular Biology 2067 Diabetic Nephropathy Methods and Protocols. 2020.

Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol 2004;286(3):F442e50.

Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med. 2004;36(1):65–70.

Lenz T, Haak T, Malek J, Gröne HJ, Geiger H, Gossmann J. Vascular endothelial growth factor in diabetic nephropathy. Kidney Blood Press Res. 2003;26(5–6):338–43.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N RD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 130(6):461–70.

Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)z. Kidney Int. 2005;67(6):2089–100.

Lissoni P, Rovelli R, Malugani F, Brivio F, Fumagalli L, Gardin GS. Changes in circulating VEGF levels in relation to clinical responce during chemotherapy for metastic cancer. Int J Biol Markers. 2003;18(2):152–5.

Mahmood AR. Oxidative stress and some trace elements in type 2 diabetes mellitus Estimation of Oxidative Stress and Some Trace Elements in Iraqi Men Patients with Type 2 Diabetes Mellitus. Iraqi J Pharm Sci. 2016;25(1):2016.

Marco GS Di, Reuter S, Hillebrand U, Amler S, Larger E, Oberleithner H, et al. The Soluble VEGF Receptor sFlt1 Contributes to Endothelial Dysfunction in CKD. 2010;2235–45.

Matsui M, Takeda Y, Uemura S, Matsumoto T, Seno A, Onoue K, et al. Suppressed soluble Fms – like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease. Kidney Int [Internet]. 2013;85(2):393–403. Available from: http://dx.doi.org/10.1038/ki.2013.339

Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: An explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol - Ren Physiol. 2007;292(6).

Nakhoul R, Nakhoul F, Nakhoul N. Diabetic Nephropathy from RAAS to Autophagy: The Era for New Players. J Clin Exp Nephrol. 2017;2(3):1–8.

Onoue K, Uemura S, Takeda Y, Somekawa S. Reduction of Circulating Soluble Fms-Like Tyrosine Kinase-1 Plays a Significant Role in Renal Dysfunction – Associated Aggravation of Atherosclerosis. 2009;

Osman WM, Jelinek HF, Tay GK, Khandoker AH, Khalaf K, Almahmeed W, et al. Clinical and genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: A cross-sectional study. BMJ Open. 2018;8(12).

Park SA, Jeong MS, Ha KT, Jang SB. Structure and function of vascular endothelial growth factor and its receptor system. BMB Rep. 2018;51(2):73–8.

S.A. Martynov, M.V. Shestakova1, I.M. Kutyrina, A.V. Ilyin1, M.I. Arbuzova IID. Role of Circulating Angiogenic Factors in Diabetic Kidney Disease. Vestn Ross Akad Med Nauk. 2013;2:35e42.

Saito Y. The role of the PlGF/Flt-1 signaling pathway in the cardiorenal connection. J Mol Cell Cardiol. 2021 Feb;151:106-112. doi: 10.1016/j.yjmcc.2020.10.001. Epub 2020 Oct 9. PMID: 33045252.

Saleh BH, Ali SH, Allehibi KI. Serum aldosterone level in patients with diabetic nephropathy in relation to vascular calcification. Iraqi J Pharm Sci. 2019;28(1):53–63.

Shao Y, Lv C, Yuan Q, Wang Q. Levels of serum 25(OH) VD3, HIF-1α, VEGF, vWf, and IGF-1 and their correlation in type 2 diabetes patients with different urine albumin creatinine ratio. J Diabetes Res, 2016, 1925424.

Sharma D, Mathur DR, Saxena DP. Evaluation of serum vascular endothelial growth factor (Vegf) and microalbuminuria in early diabetic nephropathy. Int J Adv Res Med. 2021;3(1):395–7.

Sharma D, Mathur DR, Saxena DP. Study of significance of Serum Cystatin-C and Vascular Endothelial Growth Factor as an early marker of diabetic nephropathy in type 2 diabetes patients. Int J Adv Biochem Res. 2021;5(1):09–11.

Sulaiman MK. Diabetic nephropathy: Recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr [Internet]. 2019;11(1):1–5. Available from: https://doi.org/10.1186/s13098-019-0403-4

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Tufro A, Veron D. VEGF and Podocytes in Diabetic Nephropathy. Semin Nephrol. 2012;32(4):385–93.

Ueno T, Chow LWC, Toi M. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients. Biomed Pharmacother. 2006;60(6):277–9.

Veron D., Reidy K. J., Bertuccio C., et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney International. 2010;77(11):989–999.

Zhou Z, Ju H, Sun M, Chen H, Ji H, Jiang D, et al. Serum fetuin-A concentrations are positively associated with serum VEGF levels in patients with newly diagnosed type 2 diabetes. Endocr J. 2015;62(10):879–85.